Asia’s pharma market is already worth more than $200 billion and is expected to grow strongly in the coming years. The market is incredibly diverse, from advanced economies such as Japan, South Korea, Taiwan, Singapore, Australia and New Zealand, to large and rapidly developing markets such as China, India, Indonesia, Thailand or The Philippines. The population in Asia is over 4 billion and the Asian middle class is growing very quickly. Factors such as rising incomes, increased government expenditure on healthcare and the growing incidence of chronic developed-world diseases associated with changing lifestyles, have all significantly contributed to increased healthcare demand in Asia. Therefore, many global pharmaceutical companies are looking at Asia to counter stalling or falling revenue streams in more developed markets. In order to maximize their performance in these emerging markets, pharmaceutical companies increasingly rely on medical affairs to facilitate the achievement of their goals.
DAY 1 - Best Practices in Medical Affairs Management in Asia
The roles of medical affairs and liaison have never before been so crucial to the success of pharmaceutical strategic and operational commercial objectives. Medical departments play a vital role in generating quality clinical and real-world data that payers and prescribers need to improve decision making when uncertainty is high. In Asia, medical affairs and (increasingly liaisons) also play an increasingly important role in communicating the value message to physicians in an objective and ethical manner, providing education on product benefits and risks. This is even more essential as busy doctors in the region have little time for sales pitches from commercial executives, but do often appreciate the “neutral” education of benefits vs risks that medical professionals are in a position to discuss. The medical affairs department is increasingly becoming central to the coordination of internal stakeholders (commercial, market access, regulatory, clinical development, drug safety) with the needs of external stakeholders and achieving more client-centric business models. Medical teams not only need to develop strong data, but also need to help educate KOLs and payers on the value of that data, especially for complex diseases.
Day 2 - Late Phase & Real-World Evidence Generation for Medical Affairs
Generating real-world evidence via observational studies and the use of patient registries is one of the fastest growing areas of pharmaceutical R&D internationally, as well as in Asian countries. Such post-marketing studies are becoming increasingly important as regulatory agencies and key-stakeholders demand more real-life, long-term data which demonstrates efficacy, safety and quality. Furthermore, a key driver for these types of studies are the growing demands of both global and increasingly, Asian health technology assessors (HTAs) and payers and their need for evidence-based health economic data, based on unique local conditions. As more patients than ever before in the region have access to advanced medicines, Asia is also an increasingly popular place to conduct late-phase studies, to study large real-world patients subsets and to satisfy the data requirements of regulators and HTAs in more developed markets. Planning and implementing late-phase studies are a major challenge, especially in a region with little experience in this area. Getting the trial design right is essential, as designs from Europe or The USA may not be suitable for Asian populations. Patient populations in Asia are as spread out and diverse as much as the huge market itself. Implementing real-world studies are also a major difficulty, especially in terms of patient selection and investigator recruitment. Less-experienced KOLs and physicians need detailed education on trial protocols as well as best practices in this area where experience is often limited at best. Close monitoring and effective data management is extremely crucial in ensuring the success of late-phase studies in Asia.
This event will offer a unique chance to benchmark and network with Asia’s medical affairs experts to discuss best practices in medical affairs management, KOL education, communication, engagement and data generation, specifically in an Asian context. Attendees will appreciate how to maximise the performance of medical teams, which can facilitate the enhanced productivity of other key departments, and as a result, enhance a product’s profile in the eyes of key stakeholders and customers.
Who Will Benefit:
PHARMA & MEDICAL DEVICE:
VPs, Regional & Global directors, managers of Medical Affairs, Medical Science Liaisons, Medical Education, Health Outcome & Liaison, Medical Marketing & Communications.
KOL & stakeholder engagement, Late Phase, Clinical development, Scientific Affairs, Medical Advisors, Customer Relations.